Business Wire

NY-CLARITY-AI

21.11.2022 09:01:38 CET | Business Wire | Press release

Share
Clarity AI: Legacy Data Providers Have Discrepancies of More Than 20% in 13% of Direct Emissions Data

Clarity AI, the leading global sustainability tech platform, announced today that of approximately 6,500 public companies that report direct emissions, leading data providers have discrepancies in this reported data 42% of the time, where a discrepancy is any difference of more than 1%. When increasing the discrepancy threshold to more than 20%, leading data providers have discrepancies in one out of every eight data points.

“These significant discrepancies in 13% of the data can make the carbon footprint of a climate fund increase or decrease by more than 20% and highlight the real challenges that investors face when selecting a data provider,” said Patricia Pina, Head of Product Research and Innovation at Clarity AI. “Data reliability is core to what we do, and we see huge benefits in using advanced technology to help ensure quality.”

Clarity AI identified three problem areas legacy data providers can encounter when collecting data:

  1. Human Error: Human errors account for more than 80% of the errors found. These vary in nature but some examples include: incorrect addition of category values, misinterpretation of report details, and inaccurate unit measurements (e.g., tons vs. gigatons)
  2. Inconsistent Reporting Boundaries: Data providers use boundaries (i.e., rules to decide which entities from the group to include or not, what to do with joint ventures, investments, etc.) for emissions reporting inconsistently
  3. Incomplete Disclosures: Companies publish incomplete disclosures that omit relevant emissions (e.g., Scope 3 categories, regions/offices, business lines)

“At Clarity AI we rely on technology and data to solve reliability issues. First, we curate a robust dataset of sustainability data points, which have gone through rigorous quality checks. Then, we have trained, calibrated, and validated an expert-supervised machine learning model to select the most reliable data points and filter out non-reliable data,” added Ron Potok, Head of Data Science at Clarity AI. “The flexibility of a machine learning model allows for much more complex relationships between the reliability of a data point and its features. The model analyzes the data from all angles at every level of granularity, which boosts its performance.”

Advanced technology, like machine learning, is the only scalable and efficient way to create clean, reliable data that investors can rely on. Clarity AI has trained state-of-the-art machine learning algorithms leveraging input from sustainability experts and is the only sustainability tech provider in the market with a sophisticated machine learning reliability algorithm. Moreover, the algorithms and models only get better and better with time and continuous care from advanced technology experts, because when a data point is detected as non-reliable, it is sent for external review (i.e., to the team of experts) and corrected if necessary. Then, this data will enter back the system and further train and improve the model in a virtuous cycle.

—------------

About Clarity AI

Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, organizations, and consumers. As of August 2022, Clarity AI’s platform analyzes more than 50,000 companies, 320,000 funds, 198 countries, and 188 local governments – 2-13 times more than any other player in the market – and delivers data and analytics for investing, corporate research, benchmarking, consumer e-commerce and reporting. Clarity AI has offices in North America, Europe, and the Middle East, and its client network manages tens of trillions in assets under management. clarity.ai

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221116005510/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye